Symptom Prevalence and Intensity in Breast Cancer Patients Receiving Treatment

2.50
Hdl Handle:
http://hdl.handle.net/10755/151289
Type:
Presentation
Title:
Symptom Prevalence and Intensity in Breast Cancer Patients Receiving Treatment
Abstract:
Symptom Prevalence and Intensity in Breast Cancer Patients Receiving Treatment
Conference Sponsor:Sigma Theta Tau International
Conference Year:2007
Author:Kim, Hee-Ju, PhD
P.I. Institution Name:Kyungpook National University
Title:Research Assistant
[Research Presentation] This study examined the prevalence and intensity of 20 oncologic symptoms in breast cancer patients across treatment trajectory. A secondary analysis was used.The sample included 282 breast cancer patients undergoing chemotherapy or radiation treatment. Data were collected across the treatment trajectory: at baseline (Time 1) and at two follow-up time points (Time 2 and 3) after initiating cancer therapy. 48 hours after the second and third treatments were the follow-up points for chemotherapy patients. The last week of treatment (a total of six weeks of treatment) and one month after completion of treatment were the follow-up points for radiation treatment patients. Before treatment started (at Time1), fatigue, insomnia, and pain were the most commonly experienced symptoms, with more than 50 % prevalence. At Time 2, fatigue and insomnia were the most prevalent symptoms (> 50% prevalence). In addition to fatigue and insomnia, more than 50% of patients receiving chemotherapy experienced nausea, decreased appetite, constipation, and frequent urination. In contrast, patients receiving radiation treatment most frequently experienced pain and skin damage at the treatment area, in addition to fatigue and insomnia. At time 3, fatigue and insomnia were the most common symptoms. In addition to fatigue and insomnia, nausea, decreased appetite, constipation, and urinary frequency were most prevalent in patients receiving chemotherapy (> 50% prevalence). In patients who completed radiation treatment, pain and hot flashes were most prevalent (> 40% prevalence). In terms of symptom intensity, most patients indicated that their symptoms were mild or moderate. Fatigue appears to be relatively more intense, particularly in chemotherapy patients: about 7 at the mean intensity (score range 1-10). In caring cancer patients, clinicians need to consider the dynamic nature of symptom prevalence and intensity across the treatment trajectory and across the treatment modality.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleSymptom Prevalence and Intensity in Breast Cancer Patients Receiving Treatmenten_GB
dc.identifier.urihttp://hdl.handle.net/10755/151289-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Symptom Prevalence and Intensity in Breast Cancer Patients Receiving Treatment</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2007</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Kim, Hee-Ju, PhD</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Kyungpook National University</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Research Assistant</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">heeju06@gmail.com</td></tr><tr><td colspan="2" class="item-abstract">[Research Presentation] This study examined the prevalence and intensity of 20 oncologic symptoms in breast cancer patients across treatment trajectory. A secondary analysis was used.The sample included 282 breast cancer patients undergoing chemotherapy or radiation treatment. Data were collected across the treatment trajectory: at baseline (Time 1) and at two follow-up time points (Time 2 and 3) after initiating cancer therapy. 48 hours after the second and third treatments were the follow-up points for chemotherapy patients. The last week of treatment (a total of six weeks of treatment) and one month after completion of treatment were the follow-up points for radiation treatment patients. Before treatment started (at Time1), fatigue, insomnia, and pain were the most commonly experienced symptoms, with more than 50 % prevalence. At Time 2, fatigue and insomnia were the most prevalent symptoms (&gt; 50% prevalence). In addition to fatigue and insomnia, more than 50% of patients receiving chemotherapy experienced nausea, decreased appetite, constipation, and frequent urination. In contrast, patients receiving radiation treatment most frequently experienced pain and skin damage at the treatment area, in addition to fatigue and insomnia. At time 3, fatigue and insomnia were the most common symptoms. In addition to fatigue and insomnia, nausea, decreased appetite, constipation, and urinary frequency were most prevalent in patients receiving chemotherapy (&gt; 50% prevalence). In patients who completed radiation treatment, pain and hot flashes were most prevalent (&gt; 40% prevalence). In terms of symptom intensity, most patients indicated that their symptoms were mild or moderate. Fatigue appears to be relatively more intense, particularly in chemotherapy patients: about 7 at the mean intensity (score range 1-10). In caring cancer patients, clinicians need to consider the dynamic nature of symptom prevalence and intensity across the treatment trajectory and across the treatment modality.</td></tr></table>en_GB
dc.date.available2011-10-26T10:57:39Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T10:57:39Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.